Loading...

Brilliant Violet 785™ anti-human CD4 Antibody

Pricing & Availability
Clone
OKT4 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T4
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT4_BV785_CD4_Antibody_FC_091912
Human peripheral lymphocytes were stained with CD4 (clone OKT4) Brilliant Violet 785™.
  • OKT4_BV785_CD4_Antibody_FC_091912
    Human peripheral lymphocytes were stained with CD4 (clone OKT4) Brilliant Violet 785™.
Compare all formats See Brilliant Violet 785™ spectral data
Cat # Size Price Quantity Check Availability Save
317441 25 tests 161€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317442 100 tests 317€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16. 

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Human peripheral T cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317453 and 317454).

In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.9

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. 76:4061.
  3. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  4. Cicin-Sain L, et al. 2010. J. Immunol. 184:6739. PubMed
  5. Rosenzweig M, et al. 2001. J. Med. Primatol. 30:36.
  6. Linder J, et al. 1987. Am. J. Pathol. 127:1.
  7. Boche D, et al. 1999. J. Neurovirol. 5:232. (IHC)
  8. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. USA. 76:4061. (Immunogen)
  9. Lederman S, et al. 1991. Mol Immunol. 28:1171-81.
Product Citations
  1. Sun C, et al. 2022. Nat Biomed Eng. 6:1004. PubMed
  2. Baharlou H, et al. 2022. Cell Rep. 40:111385. PubMed
  3. Ezeonwumelu IJ, et al. 2022. Int J Mol Sci. 23: . PubMed
  4. Du Bruyn E, et al. 2023. Nat Commun. 14:188. PubMed
  5. Kerns JS, et al. 2023. Bio Protoc. 13: . PubMed
  6. Jung IY, et al. 2022. Sci Transl Med. 14:eabn7336. PubMed
  7. Rivero-Hinojosa S, et al. 2021. Nat Commun. 12:6689. PubMed
  8. Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
  9. Vojtech L et al. 2019. PLoS One. 14(10):e0223901 . PubMed
  10. Schlicher L, et al. 2022. Int J Mol Sci. 23:. PubMed
  11. Lee PS, et al. 2022. MAbs. 14:2024642. PubMed
  12. Tauriainen J, et al. 2017. Sci Rep. 7:40354. PubMed
  13. Tebas P, et al. 2021. J Clin Invest. 131:. PubMed
  14. Mineo M, et al. 2020. Molecular Cell. 78(6):1207-1223.e8. PubMed
  15. Rubio-Pérez C, et al. 2021. Nat Commun. 1503:12. PubMed
  16. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  17. Gurusamy D, et al. 2020. Cancer Cell. 37(6):818-833.e9. PubMed
  18. Rajamanickam V, et al. 2021. Cancer Immunol Res. 9:602. PubMed
  19. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  20. Serwas NK, et al. 2019. Nat Commun. 2.573611111. PubMed
  21. Wang F, et al. 2021. Cell. 184(2):422-440.e17. PubMed
  22. Lutter L, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1567. PubMed
  23. Bruggen JACV, et al. 2022. Blood Adv. :. PubMed
  24. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  25. Zebley CC, et al. 2021. Cell Rep. 37:110079. PubMed
  26. Zhang Q, et al. 2021. Sci Transl Med. 13:eabg6986. PubMed
  27. Kim SP, et al. 2022. Cancer Immunol Res. :OF1. PubMed
  28. Ruella M, et al. 2018. Nat Med. 24:1499. PubMed
  29. Moravcikova E, et al. 2018. Cytometry A. 93:894. PubMed
  30. Duhen R, et al. 2021. Nat Commun. 12:1047. PubMed
  31. Wilson TL, et al. 2022. Cancer Discov. 12:2098. PubMed
  32. Adel–Patient K, et al. 2018. Clin Transl Allergy. 8:38. PubMed
  33. Darrah PA, et al. 2019. NPJ Vaccines. 4:21. PubMed
  34. Riberdy JM, et al. 2020. Mol Ther Methods Clin Dev. 1.146527778. PubMed
  35. Fierle JK, et al. 2021. Cell Reports Medicine. 2(8):100362. PubMed
  36. Li L, et al. 2022. JCI Insight. 7:. PubMed
RRID
AB_2563242 (BioLegend Cat. No. 317441)
AB_2563242 (BioLegend Cat. No. 317442)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution

T cell subset, majority of thymocytes, monocytes/macrophages

Function
MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor
MHC class II molecules, HIV gp120, IL-16
Cell Type
Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Center D, et al. 1996. Immunol. Today 17:476.
2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.

Gene ID
920 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD4
Specificity Alt (DOES NOT SHOW ON TDS):
CD4
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 4    Revision Date: 07/13/2015

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account